1Matrisian LM. The matrix-degrading metallopro-teinas[J]. Bioassay, 1992, 14:455-563.
2Akino F. Identification of the second membrane-type matrix metalloprote-inasgene froma human placente cDNA[ J ]. J Biol Chem,1995, 270: 23013-13020.
3Murawaki Y, Yamada S, Ikuta Y, et al. Clinical usefulness of serum matrix metalloproteinase - 2 concentration in patients with chronic virul liver disease[J]. J Hepatol, 1999, 30(6) : 1090 -1098.
4Kasahara A, Hayashi N, Mochizuki K, et al. Circulating matrix metalloproteinase - 2 and tissue inhibitor of metalloproteinase - 1 as serum marker of fibrosis in patients with chronic hepatitis C. Relationship to interferon response[J]. J Hepatol, 1997, 26(3): 574-583.
5Ylisirnio S, Hoyhtya M, Turpeenniemi H, et al. Serum matrix metalloproteinases- 2, - 9 and tissue inhibitors of metalloproteinases - 1, - 2 in lung cancer - TIMP - 1 as aprognostic marker[J]. Anticancer Res, 2000, 20(2B) : 1311 - 1316.
6Oberg A, Hoyhtya M, Tavelin B, et al. Limited value of preoperative serum analyses of matrix metalloproteinases(MMP - 2, MMP- 9)and tissue inhibitor of matrix metalloproteinases(TIMP - 1, TIMP - 2 )in colorectal cancer[J]. Gut, 1998, 42(5) : 715 - 720.
7Gohji K, Fujimoto N, Hara I, et al. Serum matrix metalloproteinase - 2 and its density in men with prostate cancer as a new predictor of disease extersion[ J ]. Int J Cancer, 1998, 79 ( 1 ) : 96 -101.
8Endo K, Maehara Y, Baba H, et al. Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer[J]. Anticancer Res, 1997, 17(3C) : 2253 - 2258.
9Akiyama K, Shikata K, Sngimoto H, et al. Changes in serum concentrations of matrix metalloproteinases, tissue inhibitors of metalloprotei nases and type Ⅳ collagen in patients with various types of glomerulonephritis. Res Commun Mol Pathol pharmacol, 1997, 95(2): 115 - 128.
10George DK, Ramm GA, Powell LW, et al. Evidence for altered hepatic matrix degradation in genetic haemochromatosis [ J ]. Gut,1998, 42(5): 715-720.
